久久亚洲国产成人影院-久久亚洲国产的中文-久久亚洲国产高清-久久亚洲国产精品-亚洲图片偷拍自拍-亚洲图色视频

Global EditionASIA 中文雙語Fran?ais
Business
Home / Business / Companies

World-first drug to be launched in China

By Liu Zhihua | chinadaily.com.cn | Updated: 2018-12-19 13:36
Share
Share - WeChat
A worker leaves the AstraZeneca research facility in Loughborough, the United Kingdom. [Photo/Agencies]

AstraZeneca China announced on Tuesday that new anemia drug roxadustat has received approval from the National Medical Products Administration.

The drug was developed in collaboration with FibroGen China.

China has become the first country worldwide to approve the oral anemia treatment hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI).

AstraZeneca said the drug was expected to be launched in China during the second half of 2019.

Roxadustat, Chinese brand name Ai Rui Zhuo(愛瑞卓), has achieved three primary breakthroughs: it's the first drug to the adopt the HIF mechanism; the first of its kind developed and incubated in China, and the first approved in China before any other market globally, the company said.

FibroGen China was responsible for the clinical trials and registration of roxadustat in China, and now holds the certificate of drug registration issued by the NMPA.

Following the approval, FibroGen China will manage manufacturing, medical affairs and distribution.

AstraZeneca will manage its launch and commercialization.

According to the NMPA approval, roxadustat is to be used in the treatment of anemia caused by chronic kidney disease (CKD) in patients who are dialysis-dependent (DD).The medicine can be prescribed to patients who use hemodialysis or peritoneal dialysis.

There are over 120 million CKD patients in China, and anemia is one of the complications of CKD, occurring at a rate of up to 98.2 percent in patients on dialysis, according to medical journals Lancet and Chinese Journal of Nephrology.

If anemia is not controlled, it increases cardiovascular risks, as well as mortality in patients on dialysis, and may affect patients' mental health and social functions, imposing a heavy burden on patients, their families and society.

According to clinical data in China, roxadustat can effectively increase and keep hemoglobin in dialysis patients with anemia caused by CKD, AstraZeneca said.

The development of roxadustat ends a long period in which there were no new drugs developed by a new mechanism for the treatment of CKD-caused anemia, said Chen Xiangmei, member of the Chinese Academy of Engineering and head of the PLA Institute of Kidney Diseases.

AstraZeneca also attributed the fast approval to the Chinese government's efforts in supporting pharmaceutical innovation and providing more quality new drugs to Chinese patients.

Leon Wang, executive vice president, international and China President at AstraZeneca, said: "Roxadustat's approval in China demonstrated the determination of the Chinese government in accelerating the supply of urgently needed new drugs to Chinese patients and supporting pharmaceutical innovation.

"In the future, AstraZeneca will work closely with the government to increase the accessibility of roxadustat in China and benefit more Chinese patients.

"At the same time, in response to the Chinese government's call for pharmaceutical innovation, we will build the local incubation platform to make more novel drugs benefiting Chinese patients first and open up China's pharmaceutical innovations to the world."

Chen Nan, a professor with Shanghai Jiao Tong University School of Medicine, who led principal investigator in the phase-three clinical trial of roxadustat in China, said: "Thanks to the improvement of China's pharmaceutical innovation atmosphere, Chinese researchers now have much better chance to show their excellence together with international peers, to further the global clinical development of first-in-class innovative drugs and to succeed in incubating them in China first.

"Our work is taking the lead not only in terms of speed, but also meets international standards in terms of quality, which demonstrates the research and development strength of China's healthcare professionals."

Top
BACK TO THE TOP
English
Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
CLOSE
 
主站蜘蛛池模板: 国产成人一区二区三区影院免费 | 自拍视频在线 | 免费又黄又爽视频 | 免费公开视频人人人人人人人 | 久久久久久久亚洲精品一区 | 国产手机精品视频 | 日韩性大片免费 | 亚洲日本中文字幕在线 | 欧美一级欧美三级在线观看 | 好叼操这里只有精品 | 久久综合狠狠综合久久综合88 | 亚洲天堂网在线观看 | 亚洲天堂男| 久久久www成人免费精品 | 日本欧美亚洲 | 国产理论最新国产精品视频 | 亚洲手机视频 | 国产99精品一区二区三区免费 | a级片在线免费观看 | 4455四色永久免费 | 视频一区中文字幕 | 偷拍精品视频一区二区三区 | 美女视频很黄很a免费国产 美女视频黄.免费网址 | 欧美大尺度aaa级毛片 | 欧美日韩在线观看视频 | 日韩一区二区三区不卡视频 | 特级毛片免费观看视频 | 中文字幕欧美亚洲 | 精品国产一区二区三区国产馆 | 国产人成亚洲第一网站在线播放 | 狠狠se| 亚洲资源在线 | 久久久久久久国产免费看 | 久草视频大全 | 日本高清视频www夜色资源 | 一级aaaaaa毛片免费同男同女 | 久久综合网址 | 久久免费视频精品 | 国产在线综合一区二区三区 | 网站免费满18成年在线观看 | 欧美亚洲日本视频 |